---
title: >-
  Initiation and interruption in intravenous bisphosphonate therapy among
  patients with multiple myeloma in the United States.
description: >-
  Explore this publication on real-world evidence: Initiation and interruption
  in intravenous bisphosphonate therapy among patients with multiple myeloma in
  the…
date: '2018-01-01'
category: Publications
tags:
  - Cancer Medicine
  - Abstract / Manuscript
  - R&D
  - Care
  - Methods/Pharmacoepi
  - Oncology
  - Health System Partner
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/cancer-medicine/initiation-and-interruption-in-intravenous-bisphosphonate/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: initiation-and-interruption-in-intravenous-bisphosphonate
id: 35Hm5LI0FV9qqrBuzV3XB3
contentType: article
---

## Challenge

IV bisphosphonate therapy for multiple myeloma patients is associated with significant clinical benefit, but real-world patterns of initiation, interruption, and discontinuation in US oncology practices had not been characterized.

## Solution

Target RWE researchers analyzed administrative claims data to characterize initiation and interruption patterns of IV bisphosphonate therapy in multiple myeloma patients, identifying patient- and practice-level predictors of guideline-concordant therapy management.

## Impact

Characterizing real-world IV bisphosphonate utilization patterns in multiple myeloma provides evidence of treatment gaps that oncology drug development partners can use to design supportive care studies and clinical decision support interventions.